OTCMKTS:CSLLY CSL (CSLLY) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free CSLLY Stock Alerts $94.29 +0.41 (+0.44%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$91.79▼$95.8350-Day Range$89.91▼$99.4152-Week Range$71.51▼$105.11Volume22,690 shsAverage Volume30,603 shsMarket Capitalization$91.13 billionP/E RatioN/ADividend Yield1.16%Price TargetN/A Stock AnalysisStock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort Interest Get CSL alerts: Email Address CSL MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.57Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth13.97%From $3.15 to $3.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.59 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for CSL. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently decreased by 40.23%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldCSL pays a meaningful dividend of 1.18%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthCSL does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CSL will have a dividend payout ratio of 30.36% next year. This indicates that CSL will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSLLY. Previous Next 2.5 News and Social Media Coverage News SentimentCSL has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CSL this week, compared to 1 article on an average week.MarketBeat Follows1 people have added CSL to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CSL insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.03% of the stock of CSL is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CSL are expected to grow by 13.97% in the coming year, from $3.15 to $3.59 per share.Price to Book Value per Share RatioCSL has a P/B Ratio of 5.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About CSL Stock (OTCMKTS:CSLLY)CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More CSLLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSLLY Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comVafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patientsMarch 26, 2024 | afr.comBlood giant CSL works up $US1 billion-plus bond deal; banks mandatedMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 11, 2024 | finance.yahoo.comCSL Ltd's Dividend AnalysisMarch 6, 2024 | prnewswire.comCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. SeasonFebruary 15, 2024 | markets.businessinsider.comWilsons downgrades CSL (CMXHF) to a HoldFebruary 13, 2024 | fool.com.auCSL shares tumble despite first-half earnings beatFebruary 13, 2024 | afr.comWhat we learnt from CSL, Challenger, Seek and Breville’s resultsMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…February 13, 2024 | finanznachrichten.deCSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³February 12, 2024 | fool.com.auCSL share price on watch amid 20% profit jumpFebruary 12, 2024 | marketwatch.comCSL Says 1H Profit Rises, Boosts Dividend -- UpdateFebruary 12, 2024 | afr.comCSL shrugs off trial setback to post double-digit earnings growthFebruary 12, 2024 | wsj.comCSL Profit Rises, Boosts DividendFebruary 12, 2024 | msn.comCSL Limited falls after Phase 3 setback for key trialFebruary 12, 2024 | msn.comAsian stocks move little in holiday-thinned trade; CSL drags on AustraliaFebruary 6, 2024 | msn.comCSL and Arcturus’ Covid-19 booster found to prolong immunityFebruary 5, 2024 | finance.yahoo.comNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterJanuary 29, 2024 | fool.com.auAre CSL shares set for an earnings boost?January 23, 2024 | fool.com.auIs now the right time to buy CSL shares? Here's my takeJanuary 23, 2024 | theglobeandmail.comAll hands on deck for employee growth at CSLJanuary 14, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ansell (OtherANSLF) and CSL (OtherCMXHF)January 3, 2024 | finanznachrichten.deCSL Behring Announces Availability of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled SyringeJanuary 2, 2024 | markets.businessinsider.comLoop Capital Markets Keeps Their Buy Rating on Carlisle Companies (CSL)December 21, 2023 | msn.comCSL worker held for 'spying' on Navy shipDecember 18, 2023 | ca.finance.yahoo.comQURE Jan 2024 25.000 callDecember 17, 2023 | ca.finance.yahoo.comQURE Jan 2024 5.000 callSee More Headlines Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees32,000Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.63 Current Ratio2.01 Quick Ratio0.82 Sales & Book Value Annual Sales$13.31 billion Price / Sales6.85 Cash Flow$3.20 per share Price / Cash Flow29.44 Book Value$18.48 per share Price / Book5.10Miscellaneous Outstanding Shares966,510,000Free FloatN/AMarket Cap$91.13 billion OptionableNot Optionable Beta0.73 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Paul F. McKenzie Ph.D. (Age 58)MD, CEO & Executive Director Comp: $2.75MMs. Joy Carolyn Linton B.Com. (Age 59)BComm, GAICD, Grad Dip AFI, Chief Financial Officer Comp: $2.05MMr. Mark DehringHead of Investor RelationsMr. Gregory Boss B.S. (Age 63)BS(Hons), J.D., Executive VP of Legal & General Counsel Comp: $1.1MChristina HickieSenior Manager of CommunicationsMs. Roanne ParryChief Human Resources OfficerDr. Karen Etchberger (Age 66)Executive Vice President of Quality & Business Services Comp: $1.03MMs. Jemimah BrennanHead of Communications - Asia PacificDr. Andrew D. Nash BSc (Hons) (Age 62)GAICD, Ph.D., Senior Vice President of Research Dr. William Mezzanotte M.D. (Age 65)M.P.H., Executive VP & Head of Research and Development Comp: $1.46MMore ExecutivesKey CompetitorsGSKNYSE:GSKZoetisNYSE:ZTSRegeneron PharmaceuticalsNASDAQ:REGNBristol-Myers SquibbNYSE:BMYVertex PharmaceuticalsNASDAQ:VRTXView All Competitors Should I Buy CSL Stock? CSLLY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in CSL Limited: CSL Limited operates in the biopharmaceutical and vaccines industry, which has shown resilience and growth potential, especially during global health crises. The company has a diverse product portfolio, including plasma products, gene therapies, and recombinants, catering to various therapeutic areas. Recent developments indicate that CSL Limited has been investing in research and development, potentially leading to innovative products and market expansion. CSL Limited's stock price has shown stability and a positive trend, reflecting investor confidence in the company's performance. CSL Limited has a strong international presence, with operations in multiple countries, providing geographical diversification and market stability. Cons Investors should be bearish about investing in CSL Limited for these reasons: CSL Limited's outstanding shares and institutional ownership percentage are currently not available, potentially indicating limited transparency or investor interest. The short percentage of float for CSL Limited is currently at 0, which may suggest lower market interest or trading activity compared to other stocks. CSL Limited's float size is listed as 0, which could raise concerns about liquidity and market depth for potential investors. The month-to-month change percentage in shares shorted for CSL Limited is negative, indicating a possible decrease in market sentiment towards the stock. CSL Limited's Days to Cover ratio is very low at 0.3, which may imply a higher risk of short squeezes or volatility in the stock price. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, March 27, 2024. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com. CSLLY Stock Analysis - Frequently Asked Questions How have CSLLY shares performed in 2024? CSL's stock was trading at $97.17 on January 1st, 2024. Since then, CSLLY shares have decreased by 3.0% and is now trading at $94.29. View the best growth stocks for 2024 here. Are investors shorting CSL? CSL saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 5,200 shares, a drop of 40.2% from the February 29th total of 8,700 shares. Based on an average trading volume of 64,300 shares, the short-interest ratio is presently 0.1 days. View CSL's Short Interest. Is CSL a good dividend stock? CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.09 per share and currently has a dividend yield of 1.18%. Read our dividend analysis for CSLLY. How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CSLLY) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.